ERBB2 and familial pancreatic carcinoma: As part of a pilot study, the combination of trastuzumab (TRA; anti-HER2 monoclonal antibody) and gemcitabine was well tolerated, but showed limited therapeutic benefit in 34 patients with HER2-overexpressing metastatic pancreatic cancer [16].